NMD4C Wraps up Second Year of Training Series for Canadian Neuromuscular Clinical Fellows
We’re excited to share that the second annual National Neuromuscular Lecture Series (NNLS) finished last week! The NNLS is our 38-week virtual curriculum for neuromuscular fellows, developed by the Pillar 3 curriculum and education team together with the directors of fellowship programs across Canada. In total, 32 fellows participated in this year’s lecture series, including adult and pediatric neuromuscular and physiatry fellows from programs across Canada.
Thank-you to this year’s NNLS lead Dr. Alberto Aleman, and all the moderators who helped conduct these lectures: Drs. Hernan Gonorazky, Jessica Thériault, Erin O’Ferrall, Marianne Nury, Alasdair Rathbone, Amanda Yaworski, and Mona Hnaini. We would also like to extend a thank-you to and share our appreciation of the speakers who presented during the program, and all the fellows who participated. We look forward to hosting the third annual curriculum beginning this August!
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.